Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial

IMPORTANCE: The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF). OBJECTI...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Neurol
Main Authors: Healey, Jeff S., Gladstone, David J., Swaminathan, Balakumar, Eckstein, Jens, Mundl, Hardi, Epstein, Andrew E., Haeusler, Karl Georg, Mikulik, Robert, Kasner, Scott E., Toni, Danilo, Arauz, Antonio, Ntaios, George, Hankey, Graeme J., Perera, Kanjana, Pagola, Jorge, Shuaib, Ashfaq, Lutsep, Helmi, Yang, Xiaomeng, Uchiyama, Shinichiro, Endres, Matthias, Coutts, Shelagh B., Karliński, Michal, Czlonkowska, Anna, Molina, Carlos A., Santo, Gustavo, Berkowitz, Scott D., Hart, Robert G., Connolly, Stuart J.
Format: Artigo
Language:Inglês
Published: American Medical Association 2019
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583060/
https://ncbi.nlm.nih.gov/pubmed/30958508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2019.0617
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items